No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PRCT240517C60000
- 3.40
- +0.90+36.00%
15min DelayClose May 9 16:00 ET
3.40High3.40Low
3.40Open2.50Pre Close6 Volume146 Open Interest60.00Strike Price2.04KTurnover51.22%IV1.27%PremiumMay 17, 2024Expiry Date3.00Intrinsic Value100Multiplier8DDays to Expiry0.40Time Value100Contract SizeAmericanOptions Type0.7549Delta0.0651Gamma16.58Leverage Ratio-0.1009Theta0.0098Rho12.51Eff Leverage0.0297Vega
Intraday
- 5D
- 1D
News
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Elevation Oncology (ELEV)
PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen
PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen
PROCEPT BioRobotics Is Maintained at Buy by TD Cowen
PROCEPT BioRobotics Is Maintained at Buy by TD Cowen
Piper Sandler: Maintaining the PROCEPT BioRobotics (PRCT.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $67.00 to $75.00.
Piper Sandler: Maintaining the PROCEPT BioRobotics (PRCT.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $67.00 to $75.00.
Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Raises Price Target to $75
Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and raises the price target from $67 to $75.
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (PRCT), Springworks Therapeutics (SWTX) and Omnicell (OMCL)